Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

460.87
+4.180.92%
Post-market: 482.4621.59+4.68%19:59 EDT
Volume:1.18M
Turnover:543.17M
Market Cap:116.93B
PE:30.08
High:461.26
Open:455.59
Low:450.78
Close:456.69
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.10
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:6.26
PE(LYR):30.08

Loading ...

Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says

MT Newswires Live
·
Feb 14

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-02-13

Reuters
·
Feb 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Maravai Lifesciences Holdings (MRVI) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

TIPRANKS
·
Feb 13

Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track
·
Feb 13

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Feb 13

Scotiabank Adjusts Vertex Pharmaceuticals PT to $558 From $495, Maintains Sector Outperform Rating

MT Newswires Live
·
Feb 13

Vertex Pharmaceuticals EVP Edward Morrow Atkinson III Reports Sale of Common Shares

Reuters
·
Feb 13

Kristen Ambrose, SVP & Chief Accounting Officer, Reports Disposal of Vertex Pharmaceuticals Common Shares

Reuters
·
Feb 13

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

Dow Jones
·
Feb 13

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Reuters
·
Feb 13

Vertex Pharmaceuticals Q4 Adj. EPS $5.03 Misses $5.07 Estimate, Sales $3.190B Beat $3.176B Estimate

Benzinga
·
Feb 13

Vertex posts FY2025 GAAP operating income of USD 4.17 billion

Reuters
·
Feb 13

Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Revenue $3.19B, vs. FactSet Est of $3.18B

MT Newswires Live
·
Feb 13

BRIEF-Vertex Pharmaceuticals Q4 Adjusted EPS USD 5.03 Vs. IBES Estimate USD 5.07

Reuters
·
Feb 13

Vertex Pharmaceuticals Q4 Total REV $3.19 Bln VS Ibes Estimate $3.18 Bln

THOMSON REUTERS
·
Feb 13

Vertex Pharmaceuticals: Preparing for Anticipated Near‑Term Commercialization of Povetacicept in Igan

THOMSON REUTERS
·
Feb 13

Vertex Pharmaceuticals: Expects $500 Mln or More in REV From Non-CF Products in 2026

THOMSON REUTERS
·
Feb 13